Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This trade represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Theravance Biopharma Trading Up 1.5 %
NASDAQ:TBPH opened at $9.45 on Thursday. The stock has a 50-day moving average price of $9.09 and a 200 day moving average price of $9.17. The stock has a market capitalization of $472.51 million, a P/E ratio of -9.36 and a beta of 0.14. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $10.90.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to analysts' expectations of $29.90 million. On average, research analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.
Institutional Trading of Theravance Biopharma
Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers grew its position in shares of Theravance Biopharma by 3.8% during the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after purchasing an additional 2,293 shares in the last quarter. GAMMA Investing LLC grew its holdings in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 3,281 shares in the last quarter. Wellington Management Group LLP increased its stake in Theravance Biopharma by 3.7% in the 4th quarter. Wellington Management Group LLP now owns 198,491 shares of the biopharmaceutical company's stock worth $1,868,000 after acquiring an additional 7,162 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $353,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Theravance Biopharma by 27.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company's stock valued at $1,412,000 after acquiring an additional 32,534 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $11.33.
Read Our Latest Stock Report on TBPH
Theravance Biopharma Company Profile
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
